Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Iofina Plc LSE:IOF London Ordinary Share GB00B2QL5C79 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.80 4.9% 17.125 515,778 16:35:20
Bid Price Offer Price High Price Low Price Open Price
16.30 17.95 17.95 15.80 16.45
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 23.96 -1.37 -0.90 33
Last Trade Time Trade Type Trade Size Trade Price Currency
16:29:55 O 16,666 16.30 GBX

Iofina (IOF) Latest News

More Iofina News
Iofina Takeover Rumours

Iofina (IOF) Discussions and Chat

Iofina Forums and Chat

Date Time Title Posts
05/4/202020:46iofina iodine and Canabis oil6,490
10/3/202014:47Iofina44,891
12/2/202017:27Iofina Private Investors Meeting - Cheltenham171
08/1/202008:44IOF tipsters2,645
14/11/201919:48Iofina PLC (LON:IOF) looking to build on the successes65

Add a New Thread

Iofina (IOF) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Iofina trades in real-time

Iofina (IOF) Top Chat Posts

DateSubject
05/4/2020
09:20
Iofina Daily Update: Iofina Plc is listed in the General Financial sector of the London Stock Exchange with ticker IOF. The last closing price for Iofina was 16.33p.
Iofina Plc has a 4 week average price of 10.50p and a 12 week average price of 10.50p.
The 1 year high share price is 33.60p while the 1 year low share price is currently 10.50p.
There are currently 191,858,408 shares in issue and the average daily traded volume is 932,987 shares. The market capitalisation of Iofina Plc is £32,855,752.37.
10/3/2020
09:45
superg1: Rewind back So what caused the share price to fall when iodine prices were going the other way, was it insider selling over Belize that the rest of us were oblivious too. Ignoring that, IOF as said in the RNS are about to set off on their targets phase yet, c urgent record revenue and Ebitda, bank debt to replace the current circus highly likely on favourable terms. AB is a businessman, he knows with the current team in charge he will double, treble his money and much more by holding onto his shares and do nothing more than carry on with other business. That should all happen within a year or two. So why over a disagreement (if he fails to get in) would you make a decision to sell all your shares and miss out on £2.7 mill for every 10p the share price goes up. Per £1 mill profit on a 15 PE is 7.8p on the share price SQM and the erst forecasting rises prices. What they want is to come in and talk big expansion, get the share price going and make money more quickly on a rising share price. My 'fear' would be they would soon destroy the company.
05/3/2020
14:29
superg1: Ansana I'm sure increased demand would mean faster growth but increased demand specifically for IOF. As I understand it after many conversations with IOF they effectively build plants to meet actually not anticipated demand. In other words end users are already established prior to the completion of a plant. EG this is what posters don't see, most sit fixated on share price not doing any research at all. Through all the export data I found I was able to identify the end user for the now closed Bullmine. Most of their iodine was going to a US end user, the data allowed me to identify exactly who the customer was. I sent this details to IOF as a possible new customer to approach once they lost their supply. I noted the end user upped orders as if stock piling due to the Chile issues. So for me IOF would approach US end users who have had issues with Chile suppliers and strike a deal for new iodine they will be producing. io7 and 8 the news plants are far more cost effective than io4 and 6, negotiating positions on price are strong currently. IOF have never said it but AB did. I believe they are the lowest cost producer worldwide. The lowest cost producer statement is hard to evidence for a company to out as news. How can IOF know the opex costs for all the Japanese iodine, Russia small bits, Turkmenistan and so on. They can't so the go for lower quartile comment.
26/2/2020
07:02
jasisdad: Iofina need to be much more on top of the share price. I do think Tom has done a tremendous job in stabilising the company but my concern has always been that management do not have enough skin in the game. I am sure if they were only paid by share price growth we would see much more action. It seems the share price is lagging way behind where it "should" be so what is being done about getting the story out there - a few tweets? A note every few months maintaining the target price from Finncap doesn't exactly help. What are they doing as the broker?Is it just the debt that is holding this back as so many on here give numbers detailing why the share price should be higher and yet we are where we are. It just doesn't add up if it was such a good bet why are so few coming on board!?
05/2/2020
11:12
freddiehoward: I didn't partake in the fund raise but bought at about that price in the market. My last buy was this week and I have well into 7 figures now. I don't know about the issues that various posters have with each other and can't comment. I am not a bear and really want this company to succeed. However, the fall in share price and the comments here this week have made me do more specific historical research on the company. As a result, I have 2 genuine issues that I will now wait to be resolved and one throw away thing I never really counted anyway. I think these 3 have led to share price fall. Issues:- 1. Reading the snippets from the latest Fincap report (can someone point me to where I can see the whole thing), I now reckon the derivatives business is reducing the profit i.e. is loss making taking account current iodine prices. I mean it would be losing maoney if it had to buy Iodine in at current levels. This is not what I believed a week ago and so now my profit expectations are lower. The derivatives are acting like a hedge. Nothing wrong in that as it is useful when iodine prices are falling, it's just not how I pictured the company when I invested with the derivative division adding significant value to the iodine. So my profit expectations have been set lower and so I have lowered my target for this year to 36p. Next year I'm expecting 65p. More if they get debt free and this issue is resolved. 2. Looking back, debt and its structure has been strangling this company for years. If they'd done a fund raise when the share price was over a £, we'd be loking at a very different proposition now. Last year, the management spoke in similar terms about a restructuring and managed to convert some debt to equity. To be honest, my opinion is that getting clear of debt is the driving issue here and will free the company and its management of what has clearly been a huge headache that the company has paid dearly for. Personally, I feel a fund raise would be a good option, if it solved the problem permanently. I suspect the seller thinks this and feels there is a good chance the company will go down this route. The issue then would be at what level and terms for existing holders. I'd be in for my full allocation and I am now saving for that eventuality. 3. The final point is the whole CBD thing. To say in the last update, they will form a business plan was crass. The should have at least said, published the business plan when things have materialised. My problem is, I suspect they were actually telling the truth and there has been no real business plan and the company have been like blue sky investors jumping on a hot thing. Even if it was thought through, I cannot believe it has gone to plan as none of the expected announcements have been forth coming. To me they look like a guy who has bought a pair of brightly coloured flared trousers just as punk has become popular and drain pipes came in. They are standing in a street looking daft. Fortunately, I never put any value on the CBD business and if flares ever come back in and the company looks really good, I will be chearing the roof off.
04/2/2020
23:11
pcjoe: Just in & checking my emails - first one telling me via private message that he had received an email - Further checking & I had received a likely similar or same one from Tom as follows "Thank you for being a long term Iofina shareholder. Iofina does not directly respond to market rumours, in particular individual posts on bulletin boards. To try to give you some clarity on your message I can confirm that Iofina’s Directors are committed to good corporate governance practices. Our integrity as a company and individuals are of utmost importance to us! We do not comment directly on share price (unless forced to do so by regulators). Share selling/buying are not always transparent to Iofina. Qualifying individuals which buy/sell shares and pass through certain thresholds have individual responsibilities to inform the market if they are required to do so. We publish this information once we receive this information. We plan to continue to execute our business strategies and are focused on completing IO#8. We are working diligently on debt restructure solutions and are confident we will have a firm plan in place by the time we release our full year results in Q2 2020. Iofina will communicate details of any material items to the market via RNS releases Tom Becker CEO" So a response of a type most of us would expect a Co CEO to make - The issue has been raised & has been noted - & hopefully not just by IOF but by Finncap as well - if a new Spikegate situation emerges we can certainly do our best to make it uncomfortable for them - they know who they sold the fund raise shares to - All we can do now is await developments as they unfold - H1 is going to be very interesting on a number of fronts it seems & hopefully for the right reasons
01/1/2020
11:30
dr andrewd: fft, in terms of CBD, I don’t see IOFs intentions to be a bog standard CBD player for that area of the business. For me it seems they intend to compete for the highest quality CBD and other derivatives. Remember Finncap said the following after the AGM: “CBD interest levels high. The AGM Q&A focused heavily on plans for its new IofinaEX division, which has piqued investor interest. Management has been monitoring and researching the CBD market for over two years and believes it can isolate and extract specific cannabinoids that can differentiate Iofina in the market place. Most current producers are unsophisticated and very small scale. Iofina’s skill sets should allow it to focus on the industrial scale extraction of specific, very high value, compounds such as CBN and CBG, which sell for $60,000-100,000 per kg. If commercially viable, we would expect very strong margins for these products.” My expectation is that the seeds form part of this to produce the highest quality hemp to start with. Based on the Q&A discussions I heard, IOF have all the kit to process material at an industrial scale (my AGM notes have Lance as saying half a tonne at a time) and they know how to use the kit. There are also advantages in having access both Iodine and CBD. Also the additional investment required was very small. They need to prove the process, ensure they get consistent quality and setup commercial arrangements to sell the product. IOF don’t normally confirm progress until all the boxes are ticked. My understanding is that they should be well placed to produce the compounds mentioned by Finncap. At $60-100 per gram, far more than you get for graphene in bulk, and with prices quoted per kg rather than per gram, this should have huge potential for big profits if the process can be cracked. I wait with anticipation on development, but I also wonder about the profit if you sold a tonne of these compounds, potentially 10s of millions of profit. No doubt if they crack it at scale, prices will reduce, but the potential could be huge. As I said recently, I can see iodine alone getting the IOF price back to half the previous high in the next year or so based on iodine prices of $45per kg and IO8 and IO9 being operational. If, and it is still a big if, you add CBD derived compounds in sensible bulk volumes then the all time high could be exceeded. Clearly time will tell, but hopefully over the next year we will find out. 2020 could be a very exciting time for IOF. I eagerly look forward to the developments.
02/11/2019
14:56
zendo102: The trouble with Iofina - some thoughts On a regular basis, posters arrive on this board proclaiming how Iofina is going to get to 30p, 40p, 50p in short order, and that once iodine hits $45/kg and we have IO8 and IO9 up and running, we should be looking at a share price of £1.00 per share. This is possible, but not guaranteed. The problem is that the price of iodine is not in Iofina’s control. If we have a sustained downturn in the economy, there is no guarantee that the iodine price will even rise from here. It could even fall if demand reduces. What is in Iofina’s control? Plant building and increasing production. But unfortunately, the rate of plant building has slowed almost to a stall. Gone are the wild “6 plants a year” that I remember Chris Fay arguing for some years back. We now have a very conservative one plant a year, and not even a megaplant at that, with IO8 being predicted to have production of 150-200 tonnes per year. IO9 might not start producing until well into 2021. This is no longer the exponential growth share that was once hoped for. Iofina, at least in terms of iodine, has become rather pedestrian. So what can we hope for? At 85% purity, IO8 could add 130-170 tonnes of pure iodine. Taking a current price of $33/kg and an all in cost price of $23/kg gives an additional bottom-line profit of $1.3-$1.7m profit for IO8 and something similar for IO9. In the past I’ve put Iofina’s profit on a P/E of 14-15 to work out the lift in share price, with the rather slow and linear growth in the number of plants, that notional P/E needs to be lower – say a P/E of 12. On iodine alone, this isn’t going to 40p a share any time soon unless there is an explosion in the iodine price. However, it is never good to base investment decisions on hope or things that lie outside a company’s control. So what about the new possible CBD, CBN products? Well anything could happen there and new contracts and products might give the share price a big boost. But unfortunately, we have been in similar situations before and hype has left the share price vulnerable. Previous “latest big things” have included oil mineral rights on Iofina’s land, licenses for hot and cold water contracts to drive the fracking industry, the Atlantis project, and helium to replace falling world reserves – I’m sure there are some I’ve forgotten. Yes, we’ve got Twitter pictures of TB in Belize, but we’ve had sightings of Japanese take-over specialists at Iofina plants in the past, and it all came to nothing. I’m not saying that CBD and CBN will come to nothing. What I am saying is that there has been so much speculation around this share that I suspect we won’t get much froth on speculation alone. This time we need cold hard contracts, joint ventures and profits. If this comes across as a de-ramping exercise, I don’t mean it to. I am long IOF and increased my stake in the open offer. I also don’t intend to sell for at least a couple of years - I am no trader. But that’s the point. This is not a jam tomorrow story. I now view this as a jam next week story, and patience is the name of the game. (Though I hope I'm wrong.)
04/8/2019
12:02
freddiehoward: My conservative calcs based on last years final results and latest update confirm Zendo's numbers based on PE of 15 gives a share price of 21p, increase in product shipped of 10% and increase of iodine price of 25% as per latest update. I've not used actual iodine prices, just % change. The latest update says debt is down 7.5 million which seems to be about 25% on last years debt. If I assume that the finance charge is down 25%, I get a Share price of 26p. So for me, the current price fairly values the business as it stands with no more news, but ignores any of the potential upside from additional plants, increasing iodine prices, CBD possibly higher production and margins from derivatives and non-iodine prducts. I'd expect a business with these prospects to trade on a PE of 18, which give an share price of 24p without finance charge reduction and 30p with so current share price is in the range. So for any significant jutified change/re-rating from here I'd say news is now essential. Anyway, here are my calcs laid out as in Final results. Year ended Year ended 31 December 31 December 2019 2018 Revenue from sales of iodine and iodine derivatives $20,342,077 $14,794,238 Revenue from non-iodine products $9,164,051 $9,164,051 Total revenue $29,506,128 $23,958,289 This is based on 10% increase of metric tonnes shipped from 544 to 598 and increase of iodine price by 25% (from 2019 update). Assume non-iodine remains as 2018 as I have no info on that and don't know what those products are. Can't find the COS split between iodine and non-iodine so assume they are in same proportion as sales - big assumption that can be played with. Also assume only the additional shipped volume will affect COS i.e. increased iodine price does not (it probably would because of dsales people's bonuses etc.). So non-iodine COS 2018 is 9,164,051/27,656,848 * 17,651,387 = 6,751,659 Iodine COS (2018) = $10,899,727 Iodine COS (2019 = 1.1 * $10,899,727= $11,989,700 Total COS = $18,741,360 Stick this into 2018 results Year ended Year ended 31 December 31 December 2019 2018 Note $ $ Revenue 3 29,506,128 23,958,289 Cost of sales 4 (18,741,727) (17,651,387) --------------- --------------- Gross profit 10,764,401 6,306,902 Administrative expenses 4 (5,241,033) (5,241,033) --------------- --------------- Operating profit/(loss) 5,523,368 1,065,869 Impairment expense 4 (2,592,276) (2,592,276) Finance expense 6 (3,062,982) (3,062,982) Finance income 7 974 974 Revaluation of derivative liability 19 3,214,166 3,214,166 --------------- --------------- Profit before taxation 4 3,315,719 (1,374,249) Taxation 8 0 231,233 --------------- --------------- Profit for the year attributable to owners of the parent $3,315,719 $(1,143,016) --------------- --------------- Shares in issue 191858408 EPS = 1.39p Assume PE 15 share price would be 21p Looking at update, I reckon the debt has been reduced by 25% so finance charge should be down 25%. If I do this then get a Share Price of 26p.
19/6/2019
21:44
naphar: I’ll be even more excited when we can start seeing a share price exceeding that last spike madchick. Note I am saying when and not if.i understand why Fest is saying it will take time, given all the additional shares in issue, and he might be right, but IOF share price can shift when the market dictates and I think we are in a good place for that to happen again.
09/6/2019
16:41
naphar: Well we all know IOF share price can move quickly. 64p a good target to have and would be very pleased to see that achieved!
Iofina share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
IOF
Iofina
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200405 20:35:28